Skip To Content

Study ID: NSABP B-59

Title:

Phase III trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo

Description:
You are enrolled in medical research study NSABP B-59. You are being asked to take part in this study because you have a type of breast cancer called Triple-Negative and have not had any treatment or surgery to remove the cancer. Triple-negative means that your tumor is negative for the protein HER2 and is not sensitive to hormone treatment. The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. Another purpose of this study is to test the good and bad effects of atezolizumab when added to the usual chemotherapy. Atezolizumab may keep your cancer from growing but it can also cause side effects.
Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Amy Sanford, MD,Preston Steen, MD
Disease:
Breast - Invasive
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.